PPT-The analysis of regulatory networking with non-coding RNA

Dr PoHan Lee 李柏翰 phleenarlabsorgtw National Applied Research Laboratories National Center for Highperformance Computing Division 2014040911 PRAGMA 26 Workshop. Family Inheritance. Me vs. . my brother. My . dad (my Y). Mom’s . dad. (uncle’s Y). Human ancestry. Disease risk. Genomics: . Regions . . mechanisms .  . drugs. Systems. : genes .  combinations  pathways. PHANG LAB TALK. MAY 03, 2012. Transcriptome. The collection of . all. transcripts (RNA) presents in a given cell . ~5 % codes for proteins. The rest codes other variety of RNAs. Speculation!. Most of the genome is transcribed into some form of RNAs. Quantitative evaluation of texts. Questions about content. When we talk about “cop shows” or “news” or “sports” we think about certain kinds of content. Usually, we perceive certain regularities in the content and notice when a single ‘text’ or ‘artifact’ deviates from those expectations.. Achieve. Financial Performance. Werk. , . Werk. , . Werk. – THE ROOM!. Facilitators: Jesse Gignac and Robyn Glassier . . 80% of jobs are found through networking . - Wall Street Journal . Make networking easy… . D. o for My Research?. November 5, 2013. APHA Conference. Outline of Session. Overall Goal. : Understand how qualitative data analysis software can improve the rigor of your public health research. Short introduction to qualitative analysis and computer-assisted qualitative data analysis software (CAQDAS). MedDRA. . MedDRA was developed under the auspices of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). The activities of the MedDRA Maintenance and Support Services Organization (MSSO) are overseen by an ICH MedDRA Management Board, which is composed of the six ICH parties (EU, EFPIA, MHLW, JPMA, FDA, PhRMA), the Medicines and Healthcare products Regulatory Agency (MHRA) of the UK, Health Canada, and the WHO (as Observer). . A how-to approach. Literature review. As is pretty much always the case, finding out what people have done in the past is the best way to prepare for your own research. Gives you the theoretical lay of the land. D. o for My Research?. November 5, 2013. APHA Conference. Outline of Session. Overall Goal. : Understand how qualitative data analysis software can improve the rigor of your public health research. Short introduction to . MedDRA. . MedDRA was developed under the auspices of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). The activities of the MedDRA Maintenance and Support Services Organization (MSSO) are overseen by an ICH MedDRA Management Committee, which is composed of the six ICH parties (EU, EFPIA, MHLW, JPMA, FDA, PhRMA), the Medicines and Healthcare products Regulatory Agency (MHRA) of the UK, Health Canada, and the WHO (as Observer). . MedDRA. MedDRA. ® . . trademark is owned by IFPMA on behalf of ICH. MedDRA was developed under the auspices of the International Conference on . Harmonisation. of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). The activities of the MedDRA Maintenance and Support Services Organization (MSSO) are overseen by an ICH MedDRA Management Board, which is composed of the six ICH parties (EU, EFPIA, MHLW, JPMA, FDA, . OMICS 5. th. International Pharmaceutical Regulatory Affairs , 3 - 5 August . 2015, Orlando, Florida, USA. Presented by: Mariam . Aslam. Agenda. Introduction. Definition of Regulatory Intelligence (RI). Regulatory Control Training Workshop. Regulatory Cooperation Forum. Luis Lederman. 6-10 November, 2017. Morocco. Learning Objectives. After going through this presentation the participants are expected to be familiar with:. The United States PerspectiveDisclaimer This talk represents my personal views and is not a reflection or a statement of OMB policy or positionsNancy Beck PhD DABTOffice of Information and Regulatory Inês Reis – Statistical assessor MHRA. PSI Career Young Statistician Webinar Session – 9 June 2020. Disclaimer. The views expressed in this presentation are my own and should not be understood or quoted as being made on behalf of the Medicines and Healthcare products Regulatory Agency (MHRA) or any other entity..